Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)
Saudi Arabia · Delayed Price · Currency is SAR 153.40
-2.20 (-1.41%)
May 21, 2026, 3:13 PM AST
TADAWUL:4015 Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,524 | 1,501 | 1,318 | 1,101 | 916.67 | 735.68 | |
Revenue Growth (YoY) | 9.63% | 13.81% | 19.77% | 20.09% | 24.60% | -8.65% |
Cost of Revenue | 571.38 | 565.06 | 500.31 | 399.03 | 325.19 | 260.99 |
Gross Profit | 953.1 | 935.56 | 818.17 | 701.79 | 591.49 | 474.69 |
Selling, General & Admin | 435.79 | 432.55 | 385.36 | 350.42 | 314 | 251.89 |
Research & Development | 38.7 | 38.69 | 34 | 33.39 | 32.68 | 37 |
Other Operating Expenses | -13.12 | -13.22 | -0.39 | 0.08 | - | - |
Operating Expenses | 463.79 | 460.45 | 430.35 | 385.98 | 349.03 | 288.89 |
Operating Income | 489.31 | 475.12 | 387.82 | 315.8 | 242.46 | 185.8 |
Interest Expense | -1.57 | -0.19 | -0.1 | -0.11 | -0.12 | - |
Interest & Investment Income | 4.92 | 4.41 | 6.94 | - | - | - |
Earnings From Equity Investments | 11.65 | 13.84 | 18.57 | 4.41 | -0.32 | -0.05 |
Currency Exchange Gain (Loss) | 1.19 | 1.19 | -18.75 | -1.33 | -47.95 | 2.01 |
Other Non Operating Income (Expenses) | -1.17 | -1.17 | -7.3 | -3.02 | -6.54 | 1.28 |
EBT Excluding Unusual Items | 504.33 | 493.2 | 387.18 | 315.76 | 187.53 | 189.04 |
Gain (Loss) on Sale of Investments | -0.1 | -0.1 | -4.52 | 0.04 | 0.01 | -1.04 |
Gain (Loss) on Sale of Assets | - | - | - | - | 0.03 | 0.09 |
Asset Writedown | - | - | - | - | -1.25 | - |
Pretax Income | 504.23 | 493.1 | 382.65 | 315.8 | 186.31 | 188.09 |
Income Tax Expense | 29.25 | 29.3 | 26.13 | 23.4 | 15 | 17.39 |
Earnings From Continuing Operations | 474.98 | 463.8 | 356.52 | 292.4 | 171.31 | 170.7 |
Net Income | 474.98 | 463.8 | 356.52 | 292.4 | 171.31 | 170.7 |
Net Income to Common | 474.98 | 463.8 | 356.52 | 292.4 | 171.31 | 170.7 |
Net Income Growth | 15.68% | 30.09% | 21.93% | 70.68% | 0.36% | -17.48% |
Shares Outstanding (Basic) | 70 | 70 | 70 | 70 | 70 | 10 |
Shares Outstanding (Diluted) | 70 | 70 | 70 | 70 | 70 | 10 |
Shares Change (YoY) | - | - | - | - | 600.00% | - |
EPS (Basic) | 6.79 | 6.63 | 5.09 | 4.18 | 2.45 | 17.07 |
EPS (Diluted) | 6.79 | 6.63 | 5.09 | 4.18 | 2.45 | 17.07 |
EPS Growth | 15.68% | 30.09% | 21.93% | 70.68% | -85.66% | -17.48% |
Free Cash Flow | 363.17 | 353.25 | 206.47 | 250.74 | 143.2 | 101.9 |
Free Cash Flow Per Share | 5.19 | 5.05 | 2.95 | 3.58 | 2.05 | 10.19 |
Dividend Per Share | 4.000 | 4.000 | 3.060 | 2.500 | - | - |
Dividend Growth | 30.72% | 30.72% | 22.40% | - | - | - |
Gross Margin | 62.52% | 62.34% | 62.05% | 63.75% | 64.53% | 64.52% |
Operating Margin | 32.10% | 31.66% | 29.41% | 28.69% | 26.45% | 25.26% |
Profit Margin | 31.16% | 30.91% | 27.04% | 26.56% | 18.69% | 23.20% |
Free Cash Flow Margin | 23.82% | 23.54% | 15.66% | 22.78% | 15.62% | 13.85% |
EBITDA | 532.55 | 517.11 | 424.44 | 341.7 | 266.57 | 209.63 |
EBITDA Margin | 34.93% | 34.46% | 32.19% | 31.04% | 29.08% | 28.49% |
D&A For EBITDA | 43.23 | 41.99 | 36.62 | 25.89 | 24.12 | 23.82 |
EBIT | 489.31 | 475.12 | 387.82 | 315.8 | 242.46 | 185.8 |
EBIT Margin | 32.10% | 31.66% | 29.41% | 28.69% | 26.45% | 25.26% |
Effective Tax Rate | 5.80% | 5.94% | 6.83% | 7.41% | 8.05% | 9.25% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.